Focus:
Novartis has collaborated with Amazon Web Services (AWS) to digitally transform the manufacturing, supply chain and delivery of its medicines using cloud services.
Bristol-Myers Squibb (BMS) has received breakthrough device designation for its Orencia (abatacept) drug to prevent moderate to severe acute graft-versus-host disease (GvHD).
French biotech firm ImCheck Therapeutics has raised $53m (€48m) in a Series B funding round to develop its gamma delta (γδ) T-cell-based antibodies to treat cancer and autoimmune disorders.
Korean company Hanmi Pharmaceutical has signed a licence and collaboration agreement with US-based Rapt Therapeutics for a cancer drug candidate, FLX475, in Asia.
Roche has received the US Food and Drug Administration (FDA) approval to use Tecentriq (atezolizumab) plus Abraxane and carboplatin chemotherapy to treat non-small cell lung cancer (NSCLC) patients.
German pharmaceutical firm Cheplapharm Arzneimittel has signed an agreement to acquire commercial rights for Seroquel and Seroquel XR in the US and Canada from AstraZeneca.
Drug maker Novartis could become a leader in CVD therapeutics after purchasing The Medicine Company and its Atherosclerotic cardiovascular disease therapy Inclisiran for $9.7bn Novartis recently announced plans to complete...
Neurocrine Biosciences has signed a licence and collaboration agreement valued at more than $1.7bn with Xenon Pharmaceuticals to develop epilepsy treatments.
Astellas Pharma has signed an agreement to acquire genetic drugs developer Audentes Therapeutics for a cash consideration of $3bn, or $60 per share.
The US Food and Drug Administration (FDA) has approved Cumberland Pharmaceuticals’ methotrexate products to treat adult and paediatric patients with rheumatoid arthritis, as well as adults with psoriasis.
Go Top
